• Something wrong with this record ?

Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine

E. Appiah, H. Nakamura, R. Pola, E. Grossmanová, O. Lidický, A. Kuniyasu, T. Etrych, M. Haratake

. 2021 ; 337 (-) : 546-556. [pub] 20210808

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Obstructed blood flow and erratic blood supply in the tumor region attenuate the distribution and accumulation of nanomedicines in the tumor. Therefore, improvement of these conditions is crucial for efficient drug delivery. In this study, we designed and synthesized a novel N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer conjugate of BK, which possessed adequate systemic stability and tumor-selective action required to improve the accumulation of nanomedicines in the tumor. Levulinoyl-BK (Lev-BK) was conjugated to an HPMA-based polymer via an acid-cleavable hydrazone bond (P-BK). An acid-responsive release of Lev-BK from P-BK was observed, and P-BK alone after intradermal application showed below 10% of the BK activity, thus proving a reduction in the vascular permeability activity of BK when attached to the polymer carrier. P-BK pre-treatment improved blood flow in the tumor tissue by 1.4-1.7-fold, which was maintained for more than 4 h. In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold. Furthermore, P-BK pre-treatment led to superior antitumor activity of PLD and significantly improved the survival of tumor-bearing mice. The release of BK from P-BK in the acidic milieu of the tumor was a prerequisite for P-BK to exert its effect, as the vascular permeability enhancing activity of P-BK was negligible. Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003745
003      
CZ-PrNML
005      
20220127145919.0
007      
ta
008      
220113s2021 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jconrel.2021.08.009 $2 doi
035    __
$a (PubMed)34375687
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Appiah, Enoch $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
245    10
$a Acid-responsive HPMA copolymer-bradykinin conjugate enhances tumor-targeted delivery of nanomedicine / $c E. Appiah, H. Nakamura, R. Pola, E. Grossmanová, O. Lidický, A. Kuniyasu, T. Etrych, M. Haratake
520    9_
$a Obstructed blood flow and erratic blood supply in the tumor region attenuate the distribution and accumulation of nanomedicines in the tumor. Therefore, improvement of these conditions is crucial for efficient drug delivery. In this study, we designed and synthesized a novel N-(2-hydroxypropyl)methacrylamide (HPMA)-based copolymer conjugate of BK, which possessed adequate systemic stability and tumor-selective action required to improve the accumulation of nanomedicines in the tumor. Levulinoyl-BK (Lev-BK) was conjugated to an HPMA-based polymer via an acid-cleavable hydrazone bond (P-BK). An acid-responsive release of Lev-BK from P-BK was observed, and P-BK alone after intradermal application showed below 10% of the BK activity, thus proving a reduction in the vascular permeability activity of BK when attached to the polymer carrier. P-BK pre-treatment improved blood flow in the tumor tissue by 1.4-1.7-fold, which was maintained for more than 4 h. In addition, P-BK pre-treatment increased the tumor accumulation of pegylated liposomal doxorubicin (PLD) by approximately 3-fold. Furthermore, P-BK pre-treatment led to superior antitumor activity of PLD and significantly improved the survival of tumor-bearing mice. The release of BK from P-BK in the acidic milieu of the tumor was a prerequisite for P-BK to exert its effect, as the vascular permeability enhancing activity of P-BK was negligible. Collectively, P-BK pre-treatment improved intratumoral blood flow and augmented tumor accumulation of nanomedicine, thereby resulting in a significant suppression of tumor growth. Therefore, these findings demonstrate that P-BK is a potential concomitant drug for improving the tumor delivery of nanomedicines.
650    _2
$a zvířata $7 D000818
650    12
$a protinádorové látky $x terapeutické užití $7 D000970
650    _2
$a bradykinin $x terapeutické užití $7 D001920
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a doxorubicin $x terapeutické užití $7 D004317
650    _2
$a nosiče léků $x terapeutické užití $7 D004337
650    _2
$a methakryláty $7 D008689
650    _2
$a myši $7 D051379
650    _2
$a nanomedicína $7 D050997
650    12
$a nádory $x farmakoterapie $7 D009369
650    _2
$a polymery $x terapeutické užití $7 D011108
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nakamura, Hideaki $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan. Electronic address: nhideaki@ph.sojo-u.ac.jp
700    1_
$a Pola, Robert $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
700    1_
$a Grossmanová, Eliška $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
700    1_
$a Lidický, Ondřej $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic
700    1_
$a Kuniyasu, Akihiko $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
700    1_
$a Etrych, Tomáš $u Institute of Macromolecular Chemistry, Czech Academy of Sciences, Heyrovsky Sq. 2, 162 06, Prague 6, Czech Republic. Electronic address: etrych@imc.cas.cz
700    1_
$a Haratake, Mamoru $u Faculty of Pharmaceutical Sciences, Sojo University, Ikeda 4-22-1, Nishi-ku, Kumamoto 860-0082, Japan
773    0_
$w MED00002621 $t Journal of controlled release : official journal of the Controlled Release Society $x 1873-4995 $g Roč. 337, č. - (2021), s. 546-556
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34375687 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127145915 $b ABA008
999    __
$a ok $b bmc $g 1751255 $s 1154894
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 337 $c - $d 546-556 $e 20210808 $i 1873-4995 $m Journal of controlled release $n J Controlled Release $x MED00002621
LZP    __
$a Pubmed-20220113

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...